Pharmacology of anticoagulants used in the treatment of venous thromboembolism

Journal of Thrombosis and Thrombolysis

Volumn 41, Issue 1, 2016, Pages 15-31

  Nutescu, Edith A ^a   Burnett, Allison ^b   Fanikos, John ^c   Spinler, Sarah ^d   Wittkowsky, Ann ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF THE SCIENCES   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anticoagulants; Direct oral anticoagulants (DOAC); Heparins; Mechanism of action; Pharmacology; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATAN ETEXILATE; DABIGATRAN; DALTEPARIN; DIRECT ORAL ANTICOAGULANT; EDOXABAN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; PROTAMINE SULFATE; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ADVERSE DRUG REACTION; ALLERGIC REACTION; ALOPECIA; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRADYCARDIA; CONTINUOUS INFUSION; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOCYTOPENIA THROMBOSIS; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; LIVER METABOLISM; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL CLEARANCE; RISK FACTOR; SINGLE DRUG DOSE; SPINE FRACTURE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; HEMORRHAGE;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 84954455938     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1314-3     Document Type: Article

References (88)

1. Wells PS, Forgie MA, Rodger MA (2014) Treatment of venous thromboembolism. JAMA 31(7):717–728
2. Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S
3. Hirsh J (1991) Heparin. N Engl J Med 324:1565–1574
4. Hirsh J, Bauer KA, Donati MB et al (2008) Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:141–159
5. Weitz DS, Weitz JI (2010) Update on Heparin: what do we need to know? J Thromb Thombolysis 29:199–207
6. Bussey H, Francis J et al (2004) Heparin overview and issues. Pharmacotherapy 24:103S–107S
7. Bick R (2005) Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin N Am 19:1–51
8. Hull RD, Raskob GE, Hirsh J et al (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109–1114
9. Raschke RA, Reilly BM, Guidry JR et al (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram: a randomized controlled trial. Ann Intern Med 119:874–881
10. Rosborough TK, Shepherd MF (2004) Achieving target anti-factor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 24:713–719
11. Schulman S, Beth RJ et al (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:257–298
12. Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879
13. Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th Ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e24S–e43S
14. Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184S
15. Campbell NR, Hull RD, Brant R et al (1996) Aging and heparin-related bleeding. Arch Intern Med 156:857–860
16. Walker AM, Jick H (1980) Predictors of bleeding during heparin therapy. JAMA 244:1209–1212
17. Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e326S–e350S
18. Levi M, Eerenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9:1705–1712
19. Schulman S, Bijsterveld NR (2007) Anticoagulants and their reversal. Transfus Med Rev 21:37–48
20. Protamine sulfate injection. AHFS Drug Information 2015. American Society of Health-System Pharmacists, Bethesda
21. Selleng K, Warkentin TE et al (2007) Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 35(4):1165–1176
22. Martel N, Lee J, Wells PS et al (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710–2715
23. Warkentin TE, Kelton JG (2001) Temporal aspects of Heparin-induced thrombocytopenia. N Engl J Med 344:1286–1292
24. Warkentin TE, Greinacher A et al (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:340–380
25. Weitz JI (1997) Low-molecular weight heparins. N Engl J Med 337:688–698
26. Fareed J, Hoppensteadt D, Walenga J, Igbal O, Jeske W, Sheikh T (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42:1043–1057
27. Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26(Suppl 1):31–38
28. Lovenox (enoxaparin sodium injection) prescribing information. Sanofi Aventis U.S. LLC, Bridgewater. http://products.sanofi.us/lovenox/lovenox.html. Accessed 11 August 2015
29. Fragmin (dalteparin sodium for subcutaneous injection) prescribing information. Pfizer Injectables. New York. http://labeling.pfizer.com/ShowLabeling.aspx?id=2293. Accessed 11 August 2015
30. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064–1083
31. Collignon F, Fryman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J et al (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73:630–640
32. Hasan K, Lazo-Langner A, Acedillo R, Zeller M, Hackam DG (2010) Anticoagulant response after dalteparin overdose. J Thromb Haemost 8:2321–2323
33. Wilson JM, Gilbert J, Harlan M, Bracey A, Allison P, Schooley C et al (2005) High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. Clin Appl Thromb Hemost 11:127–138
34. Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H et al (2002) The pharmacokinetics of fondaparinux sodium in health volunteers. Clin Pharmacokinet 41(Suppl 2):1–9
35. Arixtra (fondaparinux sodium solution for subcutaneous injection) prescribing information. GlaxoSmithKline. Research Triangle Park. http://www.gsk.ca/english/docs-pdf/product-monographs/Arixtra.pdf. Accessed 11 August 2015
36. Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772
37. Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE et al (2006) Effect of fondaparinux on coagulation assays: results of college of American Pathologists proficiency testing. Arch Pathol Lab Med 130:1605–1611
38. Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e120S–e151S
39. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th Edition. American college of chest physicians evidence-based clinical practice guidelines. Chest 141(suppl 2):e44s–e88s
40. Ansell J, Hirsh J, Hylek E et al (2008) The pharmacology and management of the vitamin K antagonists. American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(Suppl 6):160s–198s
41. Stirling Y (1995) Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coag Fibrinolysis 6:361–375
42. Breckenridge A, Orme M, Wessling H et al (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424–430
43. Hignite C, Uetriecht J, Tschanz C et al (1980) Kinetics of R and S warfarin enantiomers. Clin Pharmacol Ther 28:99–105
44. Chan E, McLachlan AJ, Pegg M et al (1994) Disposition of warfarin enantiomers and metabolism in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563–569
45. Warfarin Prescribing Information. Bristol-Myers Squibb. Princeton. http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed 11 August 2015
46. Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 65(4):365–375
47. Limdi NA, McGwin G, Goldstein JA et al (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321
48. Cavallari LH, Langaee TY, Momary KM et al (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87(4):459–464
49. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4):1013–1021
50. Ng VL (2009) Anticoagulation monitoring. Clin Lab Med 28:283
51. Ng VL (2009) Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med 28:253
52. Kirkwood TB (1983) Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 49:238–244
53. Hirsh J, Poller L (1994) The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 154:282–288
54. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. Am J Clin Pathol 103:358–365
55. Spinler SA, Nutescu ED, Smythe MA et al (2005) Anticoagulation monitoring Part 1:warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother 39:1049–1055
56. Wittkowsky AK (2006) Drug interactions with oral anticoagulants. In: Colman RW, Marder VJ, Clowes AW et al (eds) Hemostasis and thrombosis. Basic principals and clinical practice. 5th ed. Lippincott Williams & Wilkins, Philadelphia
57. Hansten P, Horn J (2010) Drug interactions analysis and management. Wolters Kluwer, St Louis
58. Daly AK, Aithal GP (2003) Genetic regulation of warfarin metabolism and response. Semin Vasc Med. 3:231–237
59. Pradaxa (dabigatran etexilate mesylate) prescribing information. Boehringer Ingelheim. Ridgefield. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed 12 August 2015
60. Eliquis (apixaban prescribing information). Bristol-Myers Squibb Company. Princeton, NJ and Pfizer Inc. New York. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 11 August 2015
61. Savaysa (edoxaban prescribing information). Daiichi Sankyo Inc., Parsippany. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed 13 August 2015
62. Xarelto (rivaroxaban) prescribing information. Janssen Pharmaceuticals. Titusville. https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf. Accessed 11 August 2015
63. Hellwig T, Gulseth M (2013) New oral therapies for the prevention and treatment of venous thromboembolism. AJHP 70:113–125
64. Cabral KP (2013) Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis 36:133–140
65. Funk DMA (2012) Coagulation assays and anticoagulant monitoring. ASH Education Book 1:460–465
66. Tripodi A, Siegal DM, Crowther MA, Garcia DA (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035
67. Cuker A (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. JACC 64:1128–1139
68. Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S–16S
69. Stangier J, Rathgen K, Stähle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268
70. Van Ryn J, Stangier J, Haerrter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Throm Haemost 103:1116–1127
71. Baglin T, Hillarp A, Tripodi A et al (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. JTH 11:756–760
72. Frost C, Nepal S, Wang J et al (2013) Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76(5):776–786
73. Frost C, Yu Z, Shenker A, Nepal S (2008) Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor. In: Abstract presentations: IXth world conference on clinical pharmacology and therapeutics. Can J Clin Pharmacol 15:e469. July 27, 2008 to August 1, 2008, Quebec City
74. Raghavan N, Frost C, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81
75. Frost C, Yu Z, Nepal S et al (2008) Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 48:1132
76. Frost C, Wang X, Barrett, et al. (2009) Abstracts of the XXII congress of the international society of thrombosis and haemostasis, Boston, July 2009. JTH abstract vol 7 (suppl 2): PP-MO-407
77. Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. BJCP 76:908–916
78. Frost C, Wang J, Li C et al (2009) Single-does safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther 85(suppl 1):s34
79. Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53:1–16
80. Kubitza D, Roth A, Becka M et al (2013) Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 76:89–98
81. Bounameaux H, Camm AJ (2014) Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 74:1209–1231
82. Becker RC, Yang H, Barrett Y et al (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban–an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32:183–187
83. Bathala MS, Masumoto H, Oguma T et al (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab and Disp 40:2250–2255
84. Fuji T, Fujita S, Abe Y et al (2013) Evaluation of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. J Thromb Haemost 11(Suppl 2):556
85. Parasrampuria D, Matsushima N, Chen S et al (2013) Safety, tolerability, and pharmacokinetics of edoxaban in end-stage renal disease subjects undergoing hemodialysis. J Thromb Haemost 11(Suppl 2):225
86. Mendell J, Zahir H, Matsushima N et al (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13(5):331–342
87. Morishima Y, Kamisato C et al (2015) Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 143(2):241–247
88. Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anti-coagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651